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screening for H. pylori, Hansen et al.2 reported that H. pylori
eradication resulted in a decreased ulcer incidence. Such
effect of decrease of prevalence of H. pylori and, therefore,
decrease of incidence of peptic ulcer between dialysis and
non-dialysis groups seems discrepant.1,2 We believe that
factors aside from H. pylori play an important role in the
occurrence of peptic ulcer in dialysis patients. In our 2-year
follow-up study after H. pylori eradication, we found that
peptic ulcer recurred more in dialysis patients than in non-
dialysis patients, with intention to treat analysis (8/32, 25 vs
2/64, 3.1%, P¼ 0.001, OR: 10.000, 95% CI: 1.979–50.540) or
per protocol analysis (8/29, 27.5 vs 2/64, 3.1%, P¼ 0.001,
OR: 11.429, 95% CI: 2.245–58.168).3
In addition, dialysis patients often need aspirin for
cardiovascular disease or NSAIDs for arthralgia.3,4 In
Sugimoto et al.’s study, the condition of aspirin/NSAIDs
usage is lacking; therefore, the conclusion may be misleading
when evaluating the incidence of peptic ulcer in dialysis
patients.1
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We thank Dr Tseng et al. for their useful comments and
references about the effects of Helicobacter pylori eradica-
tion therapy and the role of non-steroidal anti-inflamma-
tory drugs (NSAIDs)/aspirin in dialysis patients.1
H. pylori eradication therapy is well known to decrease
peptic ulcer incidence and recurrence in long-term
follow-up studies in both dialysis patients and patients
with normal renal function. In our study, the prevalence
of peptic ulcer in H. pylori–positive and –negative
dialysis patients was 23.3 and 12.1%, respectively; most
peptic ulcers in uninfected patients were healing to the red
scar stage, and active ulcers were rare.2 However, the
recurrence rate of peptic ulcer was reported to be much
higher in dialysis patients (25%) than in non-dialysis
patients (3%) during two years’ observation.3 These data
suggest that gastroduodenal mucosal injury in dialysis
patients occurs frequently, irrespective of H. pylori
infection.
NSAIDs/aspirin intake, systemic/local circulatory fail-
ure, hypergastrinemia, high ammonia levels, and enhanced
inflammation were considered to be the causes of mucosal
injury in H. pylori–negative dialysis patients.2 Dialysis
patients frequently receive NSAIDs/aspirin for preventing
cardiovascular diseases, and NSAIDs/aspirin should play
important roles for preventing the development of peptic
ulcer.4 In our unpublished data, most cases receiving
NSAIDs/aspirin were able to prevent active ulcer develop-
ment by acid inhibitory drugs (that is, proton pump
inhibitor and/or histamine receptor antagonist). Overall,
we recommend that both H. pylori–positive and –negative
dialysis patients receive frequent endoscopic checkups and
anti-acid drugs, especially those with a history of peptic
ulcer, hemorrhage, and use of anticoagulants and NSAIDs/
aspirin.
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Is standard GLA gene mutation
analysis definitive for the
diagnosis of Fabry disease?
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To the Editor: In their recent publication, Fervenza et al.1
outlined the relevance of a correct diagnosis of Fabry disease
for understanding an atypical phenotype in a male patient,
emphasizing that, once the correct diagnosis was suspected
during renal biopsy, they performed molecular analyses in
order to confirm the diagnosis due to the uncommon renal
presentation.
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